A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

Picoplatin

"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."

DRUG

docetaxel

"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."

Trial Locations (11)

105229

Burdenko Central Military Clinical Hospital, Moscow

117997

Russian Research Center of Radiology, Moscow

150054

State Medical Institution of Yaroslavl Region / Regional Clinical Oncology Hospital, Yaroslavl

188663

Leningrad Regional Oncology Center, Saint Petersburg

194291

Central Medical Unit #122, Saint Petersburg

194354

Therapeutic and Research Medical Center, Saint Petersburg

196247

St. Petersburg City Hospital #26, Saint Petersburg

198255

St. Petersburg City Oncology Center, Saint Petersburg

249036

Medical Radiology Research Center under the Russian Academy of Medical Sciences, Obninsk

454087

Chelyabinsk Regional Oncology Center, Chelyabinsk

Unknown

Research Institute of Urology - Ministry of Health, Moscow

Sponsors
All Listed Sponsors
lead

Poniard Pharmaceuticals

INDUSTRY